MedLumics Reveals Groundbreaking AF Ablation Study Results
Deal News | Mar 05, 2025 | Ysios Capital
MedLumics, a Madrid-based medical device company, announced promising results from its AblaView PFA Ablation System first-in-human trial for atrial fibrillation. CEO Peter Hinchliffe shared that the novel technology demonstrated a 100% predictive specificity in lesion durability at a 3-month follow-up, enhancing AF ablation safety and efficacy through real-time visualization. The study received acclaim from numerous experts, highlighting its potential to revolutionize atrial fibrillation treatment. Atul Verma, MD, and other leading cardiologists emphasized the study's findings presented in Europace, noting the transformative impact of MedLumics' optical imaging technology. In light of these results, MedLumics is preparing for a Series B funding round to advance further clinical trials. The company is supported by Ysios Capital and several other public and private investors.
Sectors
- Medical Devices
- Biotechnology
- Venture Capital
Geography
- Spain – MedLumics is a Madrid-based company, and its advancements in AF treatment are framed within the context of the country's medical device industry.
- Canada – Dr. Atul Verma from McGill University in Montreal contributed to the study, emphasizing Canada's involvement in the trial.
- France – Professor Raphael Martins of CHU Rennes is part of the study, representing French collaboration and interest.
- United Kingdom – London’s Professor Sabine Ernst praised the study results, reflecting UK engagement in Atrial Fibrillation treatment advancement.
Industry
- Medical Devices – The article centers around MedLumics, a company specializing in medical devices for atrial fibrillation treatment, specifically its AblaView PFA Ablation System.
- Biotechnology – The trial involves significant advancements in biotechnology through optical imaging techniques for lesion prediction in medical procedures.
- Venture Capital – Ysios Capital is a key backer of MedLumics, highlighting the investment aspect and venture capital involvement in advancing medical innovations.
Financials
- 15 million – MedLumics is raising a Series B funding round of 15 million to prepare for future regulatory clinical trials.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| MedLumics S.L. | Target Company | Company | A medical device company specializing in optically guided devices for cardiac treatments. |
| Ysios Capital | Investor | Company | A venture capital firm supporting MedLumics in its Series B funding round. |
| Peter Hinchliffe | CEO | Person | CEO of MedLumics, representative for the company's trial results and funding initiatives. |
| Atul Verma, MD | Investigator | Person | Electrophysiologist at McGill University, presented the study results broadly. |
| Professor Raphael Martins | Investigator | Person | Cardiologist at CHU Rennes, participant in the first-in-human trial. |
| Professor Sabine Ernst | Commentator | Person | Consultant Cardiologist at the Royal Brompton and Harefield NHS, provided expert commentary. |